Evidence map›Paper›PMID 26574517›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma.

Hilary Nicholson, Christophe Mesangeau, Christopher R McCurdy, Wayne D Bowen

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Hilary NicholsonDepartment of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island (H.N., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.).
Christophe MesangeauDepartment of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island (H.N., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.).
Christopher R McCurdyDepartment of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island (H.N., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.).
Wayne D BowenDepartment of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island (H.N., W.D.B.); and Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, Mississippi (C.M., C.R.M.) Wayne_Bowen@brown.edu.
Brown University · USUniversity of Mississippi · US

Funding

Center of Research Excellence in Natural Products Neuroscience (CORE-NPN)P20GM104932 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2012 to 2016
$10.0M
Advancing the Culture of PhD Learning & Scholarship in Biology & Health SciencesR25GM083270 · NIGMS · BROWN UNIVERSITY · PI CAMPBELL, ANDREW G., HARRINGTON, ELIZABETH O · 2008 to 2021
$7.5M
Novel Pharmacologic Interventions for Drugs of AbuseR01DA023205 · NIDA · UNIVERSITY OF MISSISSIPPI · PI MCCURDY, CHRISTOPHER R · 2007 to 2011
$1.7M
Predoctoral Training Program in Trans-Disciplinary Pharmacological SciencesT32GM077995 · NIGMS · BROWN UNIVERSITY · PI OANCEA, ELENA · 2010 to 2020
$1.7M
NIDA NIH HHS R01 DA023205NIGMS NIH HHS 1-T32 GM077995-01A2NIGMS NIH HHS P20 GM104932NIGMS NIH HHS R25 GM083270NIGMS NIH HHS T32 GM077995
6 · The paper itself

Abstract

Sigma-2 receptors are attractive antineoplastic targets due to their ability to induce apoptosis and their upregulation in rapidly proliferating cancer cells compared with healthy tissue. However, this role is inconsistent with overexpression in cancer, which is typically associated with upregulation of prosurvival factors. Here, we report a novel metabolic regulatory function for sigma-2 receptors. CM764 [6-acetyl-3-(4-(4-(2-amino-4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one] binds with Ki values of 86.6 ± 2.8 and 3.5 ± 0.9 nM at the sigma-1 and sigma-2 receptors, respectively. CM764 increased reduction of MTT [3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide] in human SK-N-SH neuroblastoma compared with untreated cells, an effect not due to proliferation. This effect was attenuated by five different sigma antagonists, including CM572 [3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one], which has no significant affinity for sigma-1 receptors. This effect was also observed in MG-63 osteosarcoma and HEK293T cells, indicating that this function is not exclusive to neuroblastoma or to cancer cells. CM764 produced an immediate, robust, and transient increase in cytosolic calcium, consistent with sigma-2 receptor activation. Additionally, we observed an increase in the total NAD(+)/NADH level and the ATP level in CM764-treated SK-N-SH cells compared with untreated cells. After only 4 hours of treatment, basal levels of reactive oxygen species were reduced by 90% in cells treated with CM764 over untreated cells, and HIF1α and VEGF levels were increased after 3-24 hours of treatment. These data indicate that sigma-2 receptors may play a role in induction of glycolysis, representing a possible prosurvival function for the sigma-2 receptor that is consistent with its upregulation in cancer cells compared with healthy tissue.

Indexed as

AnimalsBenzoxazolesCell Line, TumorGlycolysisHEK293 CellsHumansNeuroblastomaPiperazinesRatsReceptors, sigma6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo(d)oxazol-2(3H)-oneBenzoxazolesPiperazinesReceptors, sigmasigma-2 receptor

Identifiers

PMID26574517
PMCPMC4746495
OpenAlexW2196847493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.